display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - adjuvantbreast cancer - HER2-positive
breast cancer - adjuvantla/mBC - HER2 positive - 2nd Line (L2)
neratinib ExteNET ExteNET

Study type: